A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
← catalyst calendarNCT07753993 · readout in 1,507 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
7,000estimated
Sites
426
Countries
Argentina, Australia, Brazil +29
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-28 | estimated | When the study began enrolling |
| Primary completion | 2030-10-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-10-04 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Kidney Disease
Interventions
- Drug: Elecoglipron
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTo evaluate the effect of elecoglipron compared with placebo in reducing the risk of the composite of ≥ 50% sustained decline in eGFR, ESKD, or all-cause mortality
measured Event-driven, trial is estimated to be up to 4.5 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed